Several clinical and disease characteristics, such as tumor mutation burden (TMB),PD-L1 expression, tumor-infiltrating immune cells, or even neurologicalimmune-related adverse events have been proposed as predictive biomarkers fordisease response upon CPI treatment, but such concepts still lack robust evidencefor guiding proper patient selection.25 The gene discussed is CD274; the disease is neoplasm.